GSK in the news

GSK has added a new hepatology candidate to its pipeline through a collaboration, despite recent share price declines, and is considered 18% undervalued by analysts.

Berenberg kept its Buy rating and a target price of GBX 2200 for GSK plc.

GSK is accelerating its strategic transformation by investing in M&A and R&D to expand its pipeline and manage HIV patent expiry.

HUTCHMED initiated a global first-in-human trial for an antibody drug conjugate combining an EGFR-targeting antibody with a KRAS inhibitor, a program in which GSK holds commercialization rights outside mainland China.

GSK plc admitted 19,352 ordinary shares to trading on the London Stock Exchange, increasing its total ordinary shares to 4,316,311,662.

19,352 GSK ordinary shares were admitted to trading on the London Stock Exchange as part of its 2022 Share Save Plan.

GSK-owned ViiV Healthcare announced its long-acting HIV treatment Cabenuva succeeded in a late-stage trial.

GSK acquired Nuvalent to enhance its oncology portfolio with late-stage lung cancer medicines, aiming to secure future revenue growth.

GSK admitted 19,352 ordinary shares to the London Stock Exchange under its Share Save Plan, increasing total shares to 4,316,311,662.

Avalere Health appointed Wendy Jory, Ph.D., as Senior VP, Market Access to lead the market access team and advise biopharmaceutical and life sciences clients on pricing and reimbursement strategies.

AN2 Therapeutics received extended funding from the Gates Foundation to continue its collaboration with GSK on developing boron-based LeuRS inhibitors for tuberculosis treatment.

GSK experienced Q2 sales growth, but profit declined sharply due to significant impairment charges.

GSK acquires Nuvalent, a US oncology specialist, for its lung cancer assets to boost future revenue growth and offset patent expirations.

GSK's Regional President for Greater China and Intercontinental discusses the company's long-standing presence and strategic investments in Singapore, highlighting its role as a key hub for talent, manufacturing, and market access in Asia.

GSK acquired a trispecific T-cell engager from Chimagen Biosciences for up to USD 750 million to develop a multiple myeloma treatment.

GSK agreed to acquire a T-cell engager from ChImagen Biosciences for up to $750 million to develop a multiple myeloma treatment.

GSK and a retail pharmacist discuss RSV awareness, symptoms, risks, and CDC vaccination recommendations for older adults during October's RSV Awareness Month.

GSK is closing its Barnard Castle Sports & Social Club by the end of 2026 to repurpose the land for its manufacturing facilities, leading to strong opposition from the club's committee and members.

GSK has selected a liver-focused drug candidate from its collaboration with Wave Life Sciences, advancing its genetic medicine pipeline.

GSK and AN2 Therapeutics secured extended Gates Foundation funding for their collaborative research on boron-based LeuRS inhibitors for tuberculosis.